MorphoSys Announces Change in Supervisory Board Supervisory Board Nominates Walter Blättler as Successor of Andreas Plückthun
27 Mar 2007 -
MorphoSys AG announced that its current board member Professor Andreas Plückthun intends to resign from the Supervisory Board with effect of 16 May, 2007. Professor Plückthun is leaving the board at his own request, in order to devote additional time to his increasing number of academic research programs at the University of Zurich, as well as to be able to pursue other entrepreneurial opportunities. The Supervisory Board accepted Prof. Plückthun's decision with regret and thanked him for his long-lasting support and his contribution to the growth and success of the Company. As successor to Professor Plückthun, the Supervisory Board will propose the nomination of Dr. Walter Blättler, formerly Executive Vice President, Science and Technology of ImmunoGen, Inc., at the Company's next annual shareholder meeting in May. Professor Plückthun will remain connected to MorphoSys as an advisor on future technology development.
Dr. Walter A. Blättler studied chemistry at the Swiss Federal Institute of Technology, Zurich (ETH Zürich), and subsequently held a research position as a post-doctoral fellow at Harvard University, Cambridge, U.S.A. Prior to joining ImmunoGen at its newly established laboratories, Dr. Blättler held various positions at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston. In 1987 he joined ImmunoGen Inc., as Vice President and subsequently Senior Vice President, R&D. In 1996 he was promoted to Executive Vice President, Science & Technology. During his time with the company, ImmunoGen introduced several antibody-based drugs into clinical development and established several successful research and/or development collaborations with major pharmaceutical companies.
Top
Contact
Print version
PDF version
Send article
RSS-Feed